Keyphrases
B Cells
100%
Chronic Lymphocytic Leukemia
100%
Bendamustine
100%
Lymphoid Malignancies
100%
Chlorambucil
26%
Chemotherapy
20%
Adverse Events
20%
Fludarabine
20%
Quality of Life
13%
Meta-analysis
13%
Cyclophosphamide
13%
Randomized Controlled Trial
13%
Chemotherapy Regimen
13%
Follicular Lymphoma
13%
Survival Benefit
13%
Progression-free Survival
13%
Mantle Cell Lymphoma
13%
Rituximab
13%
Progressive Disease
13%
Small Lymphocytic Lymphoma
13%
Adult Patients
6%
Advanced Stage
6%
Confidence Interval
6%
MEDLINE
6%
Embase
6%
Search Methods
6%
Disease Course
6%
Prednisone
6%
Cochrane Library
6%
Risk Ratio
6%
Disease Control
6%
Selection Criteria
6%
Extracted Data
6%
Response Rate
6%
Conference Proceedings
6%
Hazard Ratio
6%
Randomized Clinical Trial
6%
Doxorubicin
6%
Lymphoma
6%
Overall Survival
6%
First Author
6%
Hazard Risk
6%
Relapsed Disease
6%
Effects on Survival
6%
Cochrane Central Register of Controlled Trials
6%
Trial Data
6%
Slow Growth
6%
Induction Therapy
6%
Clinical Heterogeneity
6%
Overall Survival of Patients
6%
Data Reporting
6%
Issue 2
6%
Ongoing Trials
6%
Marginal Zone Lymphoma
6%
Selective Reporting
6%
Lymphoplasmacytic Lymphoma
6%
Indolent Lymphoma
6%
Medicine and Dentistry
B Cell
100%
B-Cell Chronic Lymphocytic Leukemia
100%
Lymphoma
100%
Bendamustine
100%
Chlorambucil
26%
Lymphocytic Lymphoma
26%
Adverse Event
20%
Fludarabine
20%
Meta-Analysis
13%
Quality of Life
13%
Randomized Controlled Trial
13%
Cyclophosphamide
13%
Overall Survival
13%
Follicular Lymphoma
13%
Progression Free Survival
13%
Mantle Cell Lymphoma
13%
Progressive Disease
13%
Rituximab
13%
Chemotherapy
13%
Systematic Review
6%
Recurrent Disease
6%
Prednisone
6%
Immunotherapy
6%
Randomized Clinical Trial
6%
Disease Course
6%
Vincristine
6%
Hazard Ratio
6%
Doxorubicin
6%
MALT Lymphoma
6%
CHOP
6%
Waldenström's Macroglobulinemia
6%
Diseases
6%
Chemotherapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Bendamustine
100%
Lymphoma
100%
Chemotherapy
33%
Chlorambucil
26%
Lymphocytic Lymphoma
26%
Adverse Event
20%
Fludarabine
20%
Cyclophosphamide
13%
Randomized Controlled Trial
13%
Overall Survival
13%
Progression Free Survival
13%
Mantle Cell Lymphoma
13%
Rituximab
13%
Follicular Lymphoma
13%
Diseases
13%
Prednisone
6%
Immunotherapy
6%
Randomized Clinical Trial
6%
Disease Course
6%
Doxorubicin
6%
Vincristine
6%
Waldenstroem macroglobulinemia
6%
Marginal Zone Lymphoma
6%